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Abstract
Background: Adenoviruses are often used as vehicles to mediate gene delivery for therapeutic purposes, but their research
scope in hematological cells remains limited due to a narrow choice of host cells that express the adenoviral receptor (CAR).
T cells, which are attractive targets for gene therapy of numerous diseases, remain resistant to adenoviral infection because
of the absence of CAR expression. Here, we demonstrate that this resistance can be overcome when murine or human T
cells are transduced with an adenovirus incorporating the RGD-fiber modification (Ad-RGD).
Methodology/Principal Finding: A luciferase-expressing replication-deficient Ad-RGD infected 3-fold higher number of
activated primary T cells than an adenovirus lacking the RGD-fiber modification in vitro. Infection with replication-
competent Ad-RGD virus also caused increased cell cycling, higher E1A copy number and enriched hexon antigen
expression in both human and murine T cells. Transduction with oncolytic Ad-RGD also resulted in higher titers of progeny
virus and enhanced the killing of T cells. In vivo, 35–45% of splenic T cells were transduced by Ad-RGD.
Conclusions: Collectively, our results prove that a fiber modified Ad-RGD successfully transduces and replicates in primary T
cells of both murine and human origin.
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Introduction
Adenovirusesattachto hostcellsvia a cell surface receptor known
as the coxackie and adenovirus receptors (CAR) [1,2]. This
attachment is augmented by binding with integrins on the host
cell surface [3]. In 1995, Huang et al. first reported that activation of
T cells increased the expression of avb3 and avb5 integrins on their
cell surface and facilitated adenovirus mediated gene delivery [4].
Nevertheless, T cells are resistant to adenoviral infection because
they lack the CAR needed for virus attachment [5,6]. Several
attempts have been made to transduce T cells with different
recombinant adenoviruses, yet most of the existing literature is not
clear about the method used bythe virusto transduceinthe absence
of CAR [7–9]. It is known that RGD-fiber modified adenoviruses
which have an RGD-motif inserted in the HI-loop of the fiber, use
avb3a n davb5 integrins to attach to host cells [10,11]. RGD-fiber
modified viruses have been successfully used to transduce several
hematological cells, especially dendritic cells [12]. Most of these
studiesweredone with replication-deficientvirus todelivergenesfor
immunomodulation. In this study, using a murine model, we show
that RGD-fiber modified adenoviruses successfully transduce
murine T cells and efficiently replicate in the transduced cells.
T cells can be potential targets for gene therapy for a variety of
diseases including, but not limited to AIDS, hematologic
malignancies, autoimmune disorders and transplantation rejection
(reviewed by [13–15]). T cells have been targeted with retroviruses
and lentiviruses for therapeutic gene delivery [16,17]. These
attempts were only partially successful because of low viral titers,
their requirement of host cell-cycle progression to permit viral
genome integration and most importantly their inefficiency in
transducing T cells. On the other hand, adenoviral vectors are
easy to produce in higher titers and contain a well characterized
genome theoretically making them ideal for T cell transduction
[18,19]. Despite these advantages, studies that have investigated
adenoviral transduction in T cells have been discouraging [8,20].
These reports indicated that T cells required very high doses of
infection and resulted in frustratingly low levels of efficiency.
These obstacles have been attributed to the lack of CAR receptors
on the surface of T cells [5,6,21]. To overcome CAR deficiency,
several alterations have been attempted to improve adenoviral
transduction of T cells. These include, modifying the fiber-shaft to
bind to the CD3, replacing tail fibers on serotype 5 with that from
35 (Ad5F35) to target CD46, and using Lipofectamine during
transduction [22–25]. All of these mechanisms have resulted in
moderately successful increases in transduction efficiency. In
addition, transgenic murine models have been developed to
express hCAR receptors on T cells [21,26]. However, physiolog-
ically these models are unrealistic because T cells do not express
this receptor naturally. Hence, further research is warranted to
identify an efficient method of adenoviral transduction of T cells.
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introduction of an Arg-Gly-Asp (RGD)-containing peptide in the
HI loop of the fiber knob domain resulting in the ability of the
virus to utilize the avb3 and avb5 integrins during the cell entry
process [10,11]. This fiber modification has gained importance in
adenovirus-mediated immune therapy because of the ubiquitous
expression of avb3 and avb5 integrins on dendritic cells [27].
RGD-fiber modified adenoviruses (Ad-RGD) have been exten-
sively used to transduce dendritic cells both of human hemato-
poietic origin and murine origin to express immunomodulatory
factors for cancer immunotherapy [12,27–29]. T cell activation
induced expression of avb3 and avb5 integrins on cell surface has
already been known for quite some time [4]. Although reports of
successful RGD-fiber modified virus mediated gene delivery in T
cells have been reported, knowledge about viral-replication in the
transduced T cells has not yet been addressed [30].
Here, we investigated the efficiency of Ad-RGD virus to
transduce T cells from mouse splenocytes and human PBMCs that
were activated in vitro. We show that replication-deficient Ad-RGD
viruses that express a luciferase gene transduce more efficiently
than adenoviruses with wild-type fibers. In addition, oncolytic Ad-
RGD viruses also replicate in the transduced T cells. This
observation was supported by high E1A gene copy numbers,
increased hexon protein expression, viral progeny titers and
enhanced cytotoxicity of Ad-RGD transduced T cells. Treatment
of experimental mice with Ad-RGD demonstrated higher
infectivity of splenic T cells than virus with wild-type fibers. These
data indicate that Ad-RGD adenoviruses transduce T cells and
their replicative machinery is also efficiently utilized in the
transduced cells.
Materials and Methods
Ethics Statement
Human tissue was collected in accordance with a protocol
approved the Institutional Review Board (IRB) at the University of
Chicago (#13779A). All participants signed a written consent.
Animal experiments were performed according to a protocol
(#71407) that was approved by the Institutional Committee on
Animal Use at the University of Chicago.
Animals
Six- to eight-week-old male C57BL/6 (B6) mice were purchased
from The Harlan Sprague Dawley (Madison, WI). 2C TCR Tg
Rag1
2/2 transgenic mice were maintained as a heterozygous
colony by crossing with C57BL/6 Rag1
2/2 mice and screening
for expression of 2C TCR on peripheral blood lymphocytes by
flow cytometry with 1B2 clonotypic antibody. All mice were
housed in a specific pathogen-free facility at the University of
Chicago, and experiments were conducted according to federal
and institutional guidelines and with the approval of the University
of Chicago Institutional Animal Care and Use Committee.
Reagents
Tissue culture reagents were obtained from Cellgro/Mediatech
(Manassas, VA) and plastic ware from BD Biosciences (San Jose,
CA). PCR and qPCR oligos were purchased from Integrated
DNA Technologies (Coralville, IA). iScript cDNA synthesis kit was
purchased from Bio-Rad Laboratories (Hercules, CA). SYBR-
Greener RT-PCR mastermix was purchased from Invitrogen
(Carlsbad, CA). Fluorescent-labeled antibodies for flow cytometry
were purchased from eBioscience (San Diego, CA) or Millipore
(Billerica, MA). All other reagents were purchased from Sigma-
Aldrich (St. Louis, MO) and Thermo Fisher Scientific (Pittsburgh,
PA).
Recombinant adenoviruses and adenoviral constructs
The replication defective viruses AdWT-Luc, AdRGD-Luc,
Ad5/3-Luc and AdPK7-Luc and the replication competent
vectors AdWT and AdRGD viruses have been described
previously [31–35]. The replication-deficient and competent
(oncolytic) viruses were propagated in HEK293 (ATCC, Mana-
ssas, VA) and A549 cells (ATCC, Manassas, VA) respectively,
purified by CsCl gradient and titrated in HEK293 cells [36].
Activation of splenocytes and enrichment of CD8
+ T cells
2C TCR Tg Rag 1
2/2 mice were used as source of enriched
CD8
+ T cells. Splenocytes from 2C TCR Tg mice were activated
with anti-CD3 monoclonal antibody (clone 145.2C11; 1 mg/ml)
and cultured for 60 hrs in RPMI-1640 medium supplemented
with 10% FBS, 50 mM b-mercaptoethanol, L-glutamine and
antibiotics (R10F) and recombinant mouse IL-2 (rmIL2; 10 ng/
ml; Peprotech, Rocky Hill, NJ) at 37uCi n5 %C O 2 atmosphere.
Activated splenocytes were stained with CD8-PE and CD8
+ T
cells were enriched by FACS to 95–99% purity.
Preparation of PBMC and enrichment of human CD8
+ T
cells
Five to ten milliliters of fresh blood was drawn from 3 human
volunteers respectively according to University of Chicago
Institutional review Board approved protocol. The drawn blood
samples were diluted 1:1 with PBS and layered over 3 ml of
Lymphoprep
TM (Axis-Shield, Norway) and buffy coat was
separated according to manufacturer’s protocol. The buffy coat
was washed 3 times with PBS and resuspended in R10F
supplemented with recombinant human IL-2 (rhIL2; 20 U/ml;
Peprotech, Rocky Hill, NJ) @ 1610
6/ml. The cells were activated
with phorbol myristate acetate (PMA; 50 ng/ml) and ionomycin
(500 ng/ml) and CD8
+ T cells were enriched from each sample by
FACS.
Infection of CD8
+ T cells with adenoviruses
Fifty thousand enriched CD8
+ T cells were plated in each well
of a 96-well plate in R10F medium. The cells were adsorbed for
2 h by centrifuging at 1000 g with an MOI of 50 infectious units
(iu) per cell of wild-type and recombinant adenoviruses expressing
different fiber modifications [37]. The MOI was chosen from
routine laboratory titrations. After adsorption, virus-containing
medium was discarded and cells were washed twice with PBS and
incubated with fresh R10F supplemented with IL2 for different
time points at 37uCi n5 %C O 2 atmosphere.
Infection of A549 human lung carcinoma cells with
adenoviruses
A549 human lung carcinoma cells which are permissive for
adenovirus transduction were tested in parallel to the murine T
cell for transduction efficiency. In a typical experiment, 5610
4
A549 cells were plated in each well of a 24-well tissue culture plate
in Dulbecco’s Modified Eagles Medium supplemented with 10%
FBS, L-glutamine and antibiotics (D10F). After overnight cultures,
which allowed the cells to stabilize and adhere to the substratum,
culture medium was replaced with D10F containing 50 MOI of
respective replication-competent adenovirus. The cells were
incubated with virus for 2 h at 37uC in 5% CO2 atmosphere
for virus adsorption, following which the cells were washed twice
Ad-Mediated T Cell Transduction
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normal tissue culture conditions.
Transient transfection reporter assays
Activated murine T cells were transduced with a panel of
replication-deficient recombinant adenoviruses with wild-type fiber
or with different fiber modifications and expressing a luciferase
gene.50MOIofeachvirus type wasused forthestudy.Efficiencyof
adenovirus transduction was monitored by luciferase activity with
theLuicferaseAssaySystem (Promega, Madison,WI)inaccordance
with the manufacturer’s protocol. Briefly, mock and virus
transduced cells were harvested 48 h after adsorption and lysed in
a lysis buffer. Lysed cells were added to the luciferase-substrate
solution and luciferase activities were tested in a luminometer and
arepresented asRLU(relative light units)per mgof cellular protein.
Each experiment was performed with at least six replicates.
Quantitative Real-Time PCR
Activated murine or human T cells were treated with 50 MOI
of oncolytic Ad-WT and Ad-RGD adenovirus as described above
and incubated for different time-points up to 72 h. Virus
replication in the transduced T cells was evaluated by studying
relative changes of viral E1A expression after each time point.
Total DNA was extracted from mock and virus-treated cells by
DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Gene expression was
quantified by quantitative PCR (qPCR) using SYBR GreenER
PCR Master Mix (Invitrogen, Carlsbad, CA, USA) and primers
recognizing E1A region as described previously [38]. The
threshold cycle values for E1A were obtained from qPCR and
converted to the gene copy number from the standard curves.
DNA amplification was carried out using Opticon 2 system (Bio-
Rad). All samples were performed in triplicate. The data are
presented as E1A copy numbers per nanogram of total DNA of
Ad-RGD to those of Ad-WT transduced T cells [36].
Flow cytometry
Changes in expression of b3 and b5 integrins on primary
murine T cells upon activation with anti-CD3 antibody were
analyzed by flow cytometry. Briefly, naı ¨ve and anti-CD3 antibody
treated splenocytes were stained for either CD4 or CD8 T cells
with fluorescent dye-conjugated antibodies for respective markers
and co-stained with anti-mouse CD61 (b3) and anti-human/
mouse b5 antibodies conjugated with fluorescin-isothiocyanate
(FITC). Anti-hamster IgG-FITC and anti-mouse IgG1k-FITC
were used as isotype controls for b3 and b5 respectively. The data
were acquired by flow cytometry using BD FACSCalibur (BD
Biosciences) and analyzed by FlowJo software (Version 8.8.6; Tree
Star, Inc., Ashland, OR).
Mock, Ad-WT and Ad-RGD oncolytic virus transduced murine
T cells and A549 human lung carcinoma cells were tested for
hexon protein expression at 4, 16, 24, 48 and 72 h after treatment
with virus. 50 MOI of each virus type was used for the study.
Treated cells were fixed and permeabilized with ice-cold acetone-
methanol for 15 min at 4uC and then incubated with anti-
adenovirus-FITC antibody (Millipore, 1:100) for 20 min at 4uC.
Following incubation, the cells were washed twice with FACS
buffer (PBS +1% BSA+0.02% NaN3) and expression of adenoviral
hexon protein was analyzed by BD FACSCalibur. Data was
represented as percentage of cells expressing hexon protein.
Viability of oncolytic virus transduced murine T cells was tested
by annexin V/7-AAD exclusion method [39] using Annexin V
apoptosis detection kit (BD Biosciences). Mock, Ad-WT and Ad-
RGD oncolytic virus transduced murine T cells were harvested after
24, 48 and 72 h. Cells were resuspended in annexin-binding buffer
and stained with annexin V-FITC for the detection of phosphati-
dylserine expression on the cell membrane of apoptotic cells, and
counterstained with 7-amino actinomycin D (7-AAD) to test
membrane integrity, for 15 min at room temperature. Reaction
was stopped by diluting in 4x volumes of annexin-binding buffer and
cell viability was analyzed by flow cytometry. Population of cells
negativeforboth annexinV and 7-AAD was consideredtobe viable.
Cell cycle assay
To demonstrate that adenovirus replicates in transduced T cells,
we analyzed the cell cycle phases of the treated cells. T cells were
treated with 50 MOI of oncolytic Ad-WT and Ad-RGD virus and
harvested after 24, 48 and 72 h, respectively. Cells were washed
twice with ice-cold PBS and fixed in ice-cold methanol. Fixed cells
were rehydrated back with two washes of PBS and treated with
RNase (100 mg/ml; Sigma) for 15 min at 37uC. Reaction was
stopped by diluting in 3 volumes of PBS. Propidium iodide
(50 mg/ml; eBioscience) was added to the RNase treated cells and
PI dilution was analyzed immediately by flow cytometry.
Virus progeny release
As a further evidence of virus replication in transduced T cells,
viral progeny released from these cells was titrated. Culture
supernatant and cell pellets were harvested from oncolytic Ad-WT
and Ad-RGD transduced murine or human T cells at different
time-points after treatment as described above. Cell pellets were
lysed by subjecting them to repeated cycles of freeze-thaw. Viral
titers were measured from cell-free (culture supernatant) and cell-
associated (lysate) fractions of T cells on HEK293 cells using
Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA).
Animal studies
To test whether adenovirus infects T cells in vivo,2 610
7 iu of
Ad-WT or Ad-RGD virus was injected via tail vein in two separate
groups of 6–8 weeks old C57/B6 mice [26]. A third group
received only PBS and was designated as the Mock group. Three
animals from each group were sacrificed at 0, 3, 6, 9, 16, 24, 72
and 96 h after injection and spleens were harvested. Single cell
splenocyte suspensions were stained for CD4 and CD8 surface
markers. The cells were then stained for hexon expression as
described above. Populations of CD4
+ and CD8
+ T cells in the live
gate that were expressing hexon antigens at each time point were
analyzed by flow cytometry. The method for analyzing primary T
cells in live gate has been described earlier [40].
Statistical analysis
GraphPad Prism software package for Windows (version 4.0;
GraphPad Software, La Jolla, CA) was used to run ANOVA, two-
tailed unequal variance t test, Student’s t test, standard deviation
and standard error of measurement on the data presented. A value
of p,0.05 was considered significant.
Results
b3 and b5 integrin expression on murine primary T cells
Naı ¨ve and activated murine T cells were tested for the
expression of b3 and b5 integrins on their surface. These integrins
are components of cell-surface receptors for Ad-RGD viruses.
Flow cytometric analysis showed 3.5-fold increase in mean
fluorescence intensity of b3 and 1.5-fold increase in b5 expression
on activated CD4
+ T cells over naı ¨ve cells. In CD8
+ T cells, 2.5-
fold increase in both b3 and b5 expression was observed after
activation with anti-CD3 antibody (Fig. 1).
Ad-Mediated T Cell Transduction
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modified adenovirus
To test the transduction efficiency of adenoviruses, activated
CD8
+ T cells were enriched from mouse splenocytes and were
treated with a panel of replication-deficient recombinant adeno-
viruses with wild-type fiber or with fiber modifications, and
expressing a luciferase gene. Forty-eight hours after virus
treatment, the luciferase activity was measured from the treated
cells upon incubation with a substrate as described in materials
and methods. Maximum luciferase activity was observed in the
cells that were transduced with RGD fiber modified adenovirus
(AdRGD-Luc), which was appreciably higher than cells that were
treated with adenovirus with wild-type fiber (AdWT-Luc).
However, both of these treatments showed a statistically
significantly higher luciferase activity than either mock or
treatment with Ad5/3-Luc and AdPK7-Luc. This trend was
Figure 1. b3 and b5 integrin expression on primary murine T
cells. (A) Flow cytometry profile of b3 and b5 integrin expression on
naı ¨ve and activated primary murine T cells. Left panel shows histograms
for b3 integrins on CD4
+ (top) and CD8
+ T cells (bottom). Right panel
shows b5 integrins on CD4
+ and CD8
+ T cells. (B) Bar diagram
representation of b3 and b5 integrin expression on T cells. Top panel
s h o w si n t e g r i ne x p r e s s i o no nC D 4
+ T cells while bottom panel
represents CD8
+ T cells. White bars indicate naı ¨ve T cells and black
bars are activated T cells. Error bars indicate mean 6 SD. (*p,0.05)
doi:10.1371/journal.pone.0018091.g001
Figure 2. Primary murine CD8+ T cells can be transduced with
RGD-modified adenovirus. (A) Primary mouse T cells were treated
for 48 h with replication-deficient fiber-modified adenoviruses encod-
ing luciferase gene. Luciferase activity was measured from lysates of
treated cells and is represented as relative luciferase unit (RLU) per
milligram of cell protein. Cells transduced with RGD-modified adeno-
virus (AdRGD-Luc) showed maximum luciferase activity. (*p,0.05)
(**p,0.001). (B) Flow cytometric dot-plots showing mean fluorescence
intensity of viral hexon proteins expressed by transduced T cells. Gates
were drawn by excluding the mock-transduced cells (Mock) represent-
ed in the left panel. T cells that were transduced with oncolytic
replication-competent adenovirus with wild type fibers (Ad-WT) are
represented in the middle panel while cells transduced with RGD-fiber
modified oncolytic adenovirus (Ad-RGD) are shown in right panel. (C)
Bar diagrammatic representation of viral hexon MFI in adenovirus
induced murine T cells. Ad-RGD transduced T cells expressed 2.6-fold
more viral hexon proteins in comparison to Ad-WT transduced cells
(*p,0.01). Error bars indicate mean 6 SD.
doi:10.1371/journal.pone.0018091.g002
Ad-Mediated T Cell Transduction
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experiment (Fig. 2A).
We also tested transduction efficiency of replication-competent
oncolytic adenoviruses with either wild-type fiber (Ad-WT) or
RGD-modified fiber (Ad-RGD). Successful transduction of
oncolytic Ad-RGD in T cells was established when adenoviral
hexon proteins were expressed in cells at different-time points after
virus adsorption. Flow cytometric analysis of viral hexon antigen
expressed by the Ad-RGD treated T cells was 2.6-fold higher vs.
Ad-WT treated cells (Fig. 2B, C).
Ad-RGD replication in transduced T cells
To show that RGD-fiber modified adenoviruses not only
transduce, but also replicate in mouse T cells, anti-CD3-activated
T cells were treated with oncolytic Ad-RGD virus and tested for
expression of viral components after different time-points.
Figure 3. Evidence of adenovirus replication in Ad-RGD transduced T cells. (A) Increased adenoviral E1A gene copy number in Ad-RGD
treated cells (black bar) in comparison to Ad-WT treated cells (white bar) at different time-points after virus transduction calculated by qPCR. 24-fold
higher viral E1A gene copy number was observed in Ad-RGD treated cells versus Ad-WT transduced cells at 24 h time-point (*p,0.001). (B) Bar
diagram of flow-cytometric analysis showing percentage of T cells expressing viral hexon antigen at different time-points after virus transduction. Ad-
RGD transduced T cells are represented by black bars and Ad-WT treated cells by white bars. (*p,0.0001; ns not significant). (C) Viral progeny was
measured from cell lysate (cell-associated; upper panel) and culture supernantant (cell-free; lower panel) of adenovirus infected T cells. 16- to 21-fold
increase in viral progeny was measured in T cell lysates and 64- to 77-fold higher viral progeny was observed in cell-free fractions of Ad-RGD treated
cells (black bars) when compared to cells treated with Ad-WT (white bars) at different time-points after virus transduction (p,0.001; ND not detected).
(D) Viability of virus-transduced T cells was assessed by Annexin/7AAD exclusion method. Frequencies of Annexin/7AAD double negative cells
observed in flow-cytometry were plotted in a bar diagram. 1.8-fold and 2.8-fold higher death of Ad-RGD transduced T cells (black bars) was observed
at 48 and 72 h after virus transduction respectively, when compared to Ad-WT transduced T cells (white bars). Mock (patterned bars) and Ad-WT
showed similar viability through the entire time-course observation (*p,0.05; **p,0.001; ns not significant). Error bars represent mean 6 SD.
doi:10.1371/journal.pone.0018091.g003
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replication efficiency was suggested by measuring viral E1A gene
copy numbers by qPCR at 4, 16, 24, 48 and 72 h post-adsorption.
We observed 1.7610
5 E1A copies/ng DNA in Ad-RGD treated
cells at 4 h after virus treatment. The levels of E1A copy number
in Ad-RGD transduced cells peaked at 24 h (6.8610
5 copies/ng
DNA) which was 24-fold higher than observed in Ad-WT treated
cells. In the following time-points studied, Ad-RGD E1A copy
numbers were reduced to 2.5610
5 and 1.8610
5 copies/ng DNA
at 48 and 72 h, respectively. In comparison, these numbers were
still significantly higher than those of Ad-WT virus, which failed to
replicate efficiently in murine T cells (Fig. 3A). This further
asserted the non-permissiveness of these cells to adenoviruses with
wild-type fibers.
Similar results were observed when primary human CD8
+ T
cells were treated with Ad-WT and Ad-RGD. E1A copy numbers
of Ad-RGD virus were significantly higher than Ad-WT as early as
24 h post-transduction and increased even more by 48 h (Fig. 4).
However, the ability of both Ad-WT and Ad-RGD viruses to
replicate in A549 cells was more efficient than murine T cells. E1A
copy numbers of both viruses obtained from A549 cells were
several magnitudes higher than those from murine T cells
(Supplementary Figure S1A).
Kinetics of Ad-RGD replication was further analyzed by
measuring viral hexon protein in transduced T cells. Although
hexon antigen was observed as early as 4 h after virus treatment,
there was no difference in the percentage of T cells that were
transduced with either Ad-WT or Ad-RGD treated cells.
However, 16 h after transduction, 50% and by 24 h almost 80%
of the Ad-RGD transduced T cells were hexon-positive and this
trend was continued at the later time-points studied. In
comparison, less than 1% of the Ad-WT transduced T cells were
hexon-positive for all of the time-points studied (Fig. 3A, B). The
levels of hexon expression by both Ad-WT and Ad-RGD viruses
were very similar in A549 cells and by 24 h post-transduction,
more than 80% of both the virus-treated groups were hexon-
positive (Supplementary Figure S1B).
Higher viral progeny titer from Ad-RGD transduced T
cells
The efficiency of Ad-RGD viral replication was confirmed by
titration of the viral progeny released from the transduced T cells.
This method has been often used as a measure of viral replication
[41,42]. Viral progenies were measured in the cell-free and cell-
associated fractions of Ad-WT and Ad-RGD transduced mouse T
cells that were harvested after 4, 16, 24, 48 and 72 h of treatment.
Titration of viral progeny in respective fractions from each time-
point was performed on HEK293 cells. Results indicated a 16-fold
higher viral progeny in cell-associated fractions of Ad-RGD
treated cells compared to Ad-WT treated cells that were harvested
as early as 24 h after T cell incubation. The viral progeny titers
were further increased by 19- and 21-fold over Ad-WT progenies
at 48 and 72 h, respectively. In cell-free fractions (T cell culture
supernatants), however, a 77-fold higher viral titer was obtained
from Ad-RGD treated cells when compared to that of Ad-WT
treated cells at the 24 h time-point. This trend was maintained in
the cell-free fractions from two time-points at 48 and 72 h
(Fig. 3C). At earlier time-points, no significant difference in viral
progenies of both Ad-WT and Ad-RGD was observed.
Human primary T cells yielded a 36 to 60-fold higher viral
progeny when transduced by Ad-RGD in comparison to Ad-WT
as early as 24 h post-transduction. The difference was reduced at
48 h but increased viral progeny from Ad-RGD transduced cells
was observed again after 72 h after transduction (Fig. 5).
Figure 4. Adenoviral E1A copy numbers in transduced human
CD8
+ T cells. Increased adenoviral E1A gene copy number in Ad-RGD
treated cells (black bar) in comparison to Ad-WT treated cells (white bar)
at different time-points after virus transduction calculated by qPCR.
Samples 1–3 are three independent experiments. (*p,0.001;
** p,0.05). Error bars represent mean 6 SD.
doi:10.1371/journal.pone.0018091.g004
Ad-Mediated T Cell Transduction
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e18091Viability of Ad-RGD transduced T cells
Increasing cytotoxicity of Ad-RGD treated T cells was also a
proof of viral replication in activated murine T cells. Viability of
virus and mock-treated T cells was analyzed by annexin V/7-AAD
exclusion method and by flow cytometry. At 24 h after infection,
although there was no difference in viability of cells between the
two-treatment groups, 1.8-fold more Ad-RGD treated T cells were
dead. By 72 h less than 25% of the Ad-RGD treated cells were
alive, which was 2.8-fold less than the Ad-WT treated cells.
However, more than 75% of the mock treated cells were alive at
all the time-points studied. (Fig. 3D)
T cell transduced with oncolytic Ad-RGD undergo rapid
cell cycle progression
We performed a cell cycle analysis of T cells that were treated
with oncolytic Ad-WT, Ad-RGD viruses to test the replication
efficiency in the transduced cells. Virus treated cells were stained
with propidium iodide to evaluate their cell cycle phases by flow
cytometry. Propidium iodide binds to the cellular DNA and the
intensity of propidium iodide indicates the levels of DNA in a
particular phase of the cell cycle. The results showed that 25–30%
of the Ad-RGD treated cells were in G0/G1 and S-phase
respectively at 24 h and 48 h after virus treatment while 60–
70% of the Ad-WT treated T cells were quiescent during the
entire study period. At 72 h, most of the Ad-RGD treated cells
were out of G0/G1 and S phase and accumulated in the quiescent
phase, which corroborates with viability results where more than
67% of these cells were dead or dying (Fig. 6). Since virus utilizes
the cell’s cycling machinery to replicate, this rapid cycling of Ad-
RGD transduced T cells supports the notion that the virus
replicates in the cells.
Efficient transduction of mouse T cell by Ad-RGD virus in
vivo
To test whether transduction of T cells by Ad-RGD could be
replicated in vivo, B6 mice were injected with either PBS (Mock) or
Ad-WT or Ad-RGD virus. Animals were sacrificed at different
time-points after treatment. Splenocytes were stained for CD4 and
CD8 and both the populations were counterstained for intracel-
lular expression of viral hexon proteins. CD4
+ and CD8
+ T cells
that were present in the live gate of forward-scatter/side-scatter
flow cytometric dot plot were analyzed for hexon expression.
Significantly higher hexon staining was observed in mice from Ad-
RGD treated group, as early as 3 h after injection, when
compared to Ad-WT treated mice. Nearly 35% of splenic CD4
+
and 45% of CD8
+ T cells from Ad-RGD treated mice were hexon-
positive after 9 h of virus injection. However, these high levels
were transient, and by 16 h the numbers came down to 20% in
both CD4 and CD8 populations, but higher hexon expression was
observed in T cells of Ad-RGD treated mice after 72 h of virus
injection. The T cells from Ad-WT treated group showed minimal
hexon expression and followed the same pattern as T cells from
mock-treatment animal group (Fig. 7).
Discussion
The observations in this study are remarkable because they
show (1) that murine T cells can be transduced with human
Figure 5. Viral progeny release from transduced human CD8
+ T
cells. Viral progeny was measured from culture supernantant of
adenovirus infected human T cells. 36- to 60-fold increase in viral
progeny was measured in supernatants of T cell lysates treated with
Ad-RGD (black bars) when compared to cells treated with Ad-WT (white
bars) at 24 h after virus transduction. Samples 1–3 are three
independent experiments (*p,0.001; ** p,0.01). Error bars represent
mean 6 SD.
doi:10.1371/journal.pone.0018091.g005
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replicate in the T cells.
We chose to use the murine system primarily because of the
availability of a T cell repertoire that can be easily manipulated
both in vivo and ex vivo. Additionally, the investigation of adenovirus
replication in a murine system has yet to be studied. CD8
+ T cells
were chosen for most of our experiments, based on observation of
equally high increase in expression of both b3 and b5 integrins
upon activation with anti-CD3 antibody (Fig. 1).
RGD-fiber modified (Ad-RGD) virus showed maximum
transduction efficiency when activated T cells were incubated ex
vivo with a panel of replication-deficient adenoviruses with different
types of fiber modifications to deliver a luciferase gene (Fig. 2A).
These results support the recent report by Ye et al, [30] who
transduced CTLs with replication-deficient Ad-RGD to deliver
TNF-a gene for immunotherapy of lung tumors. However, in
another experiment, where murine T cells were exposed to
oncolytic replication-competent Ad-RGD virus, higher levels of
viral hexon proteins were expressed when compared to those of
Ad-WT virus (Fig. 2B, C). This further confirmed successful
transduction efficiency of Ad-RGD virus in murine T cells.
We aimed our study to examine the replication of the virus in
the transduced T cells. We chose onolytic Ad-WT, with wild-type
fiber and Ad-RGD. Our laboratory and others have regularly used
the method of measuring viral E1A copy number as a marker for
viral replication [36,38]. Not only did Ad-RGD transduce better
in murine T cells, kinetics of viral E1A gene copy number showed
a 24-fold increase over Ad-WT in the transduced cells (Fig. 3A).
Hexon protein expression in transduced cells is also used to
measure viral replication [43]. Therefore, we further tested the
viral replication efficiency in murine T cells by measuring the
levels of adenoviral hexon expression. Higher percentages of Ad-
RGD treated cells expressed the viral hexon protein than Ad-WT
treated cells, confirming the replicative property of Ad-RGD in
murine T cells (Fig. 3B).
The most compelling evidence of viral replication in the
transduced T cells was demonstrated in the viral progeny studies
(Fig. 3C). Cell-associated fraction, i.e., cell lysates of Ad-RGD
transduced T cells isolated between 24 and 72 h of transduction
produced 16- to 21- fold higher viral progeny vs. Ad-WT treated
cells. The Ad-RGD viral progeny titers were further enhanced to
77-fold over Ad-WT when cell-free fractions from 24 h time-point
were measured. This proves that viral replication in transduced
cells depends upon the efficiency of the virus to enter the host cells,
as AD-WT virus failed to replicate because of poor transduction
efficiency.
We observed similar transduction effect of Ad-RGD virus in
human T cells isolated from PBMCs of healthy donors. Expression
of high viral E1A copy numbers and 36 to 60-fold increased viral
progeny from Ad-RGD transduced T cells over those treated with
AD-WT confirmed that this transduction efficiency effect was not
host-species specific (Fig. 4 and 5). However, the total progeny
yield from Ad-RGD transduced human T cells was very low. This
observation could be explained by previous reports from Good-
ing’s group, where the authors have described a post-internaliza-
tion latency in viral reproduction in T cells isolated from tonsils of
infected patients as well as human T cell lines [44–46].
Ad-RGD transduced T cells also cycled faster than the Ad-WT
transduced cells as evident from the cell cycle assay. Because
replicating virus utilizes host cell’s replication machinery to
propagate [18], we hypothesized that Ad-RGD stimulated the
host cells to enter S phase of the cell cycle to provide an optimal
intracellular environment for viral reproduction. This hypothesis
was also partly based on our earlier observations of higher E1A
copy numbers and hexon protein expression in these cells. Cell
cycle analysis confirmed our hypothesis. Ad-RGD transduced T
cells were found mostly in the S- and G0/G1 phase after 24 h of
treatment, while the Ad-WT cells were mostly quiescent (Fig. 6).
Seventy-two hours after treatment with Ad-RGD, the cells were
released from the S phase and there was an increase in quiescent
Figure 6. T cells transduced with oncolytic Ad-RGD undergo rapid cell cycle. (A) Flow cytometric profile of propidium iodide (PI) dilution in
virus-transduced T cells at different time-points after treatment. Gates drawn on different cell-cycle phases are M1 sub-G0, M2 G0/G1, M3 S, M4 G2/M
and M5 quiescent. Left panel shows cells treated with adenovirus with wild-type fiber (Ad-WT). Right panel shows cells with RGD-modified oncolytic
virus (Ad-RGD). (B). Bar diagram representation of the cell-cycle. Top panel represents cells treated with Ad-WT. Bottom panel represents cells treated
with Ad-RGD. White bars are cells after 24 h, while patterned and black bars are cells after 48 and 72 h respectively after virus transduction. Error bars
represent mean 6 SD.
doi:10.1371/journal.pone.0018091.g006
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by this time.
To test virus-induced cell death, we tested the viability of virus-
transduced T cells. Ad-RGD oncolytic virus enhanced the death of T
cells upon successful transduction. At 72 h post-treatment, more than
75% of the Ad-RGD transduced cells were dead while the .75% of
Ad-WT treated cells were still viable (Fig. 3D). This observation also
confirmed that oncolytic Ad-RGD virus were successful in replicating
and propagating inside transduced murine T cells.
Our in vivo observations also corroborated with our ex vivo
results. We treated a cohort of C57/B6 mice with either Ad-WT
or Ad-RGD virus following a regimen of in vivo virus injection
reported previously [26]. PBS was injected in the mock-treatment
group. Starting 3 h after injection, a higher percentage of both
CD4
+ and CD8
+ splenic T cells that were injected with Ad-RGD
virus started expressing viral hexon proteins. Maximum transduc-
tion efficiency was observed after 9 h of injection following which
there was rapid loss of hexon-epressing T cells, which was
probably due to rapid viral clearance. Ad-WT injected mice,
however, failed to show any hexon protein in the splenic T cells
which was similar to the PBS-treated animals (Fig. 7). This
observation confirms that RGD-fiber modified recombinant
adenoviruses are capable of infecting murine T cells in vivo.
Collectively, this study shows for the first time that human
adenoviruses can not only successfully transduce T cells, they can
also efficiently replicate in the transduced cells. However, the
transduction efficiency is strictly limited to the recombinant
adenoviruses that have been modified to express the RGD-motif
on the viral fiber. This RGD-fiber modification utilizes increased
b3 and b5 integrin expression in activated T cells to attach and
enter the host cells. This study along with our recent report of
cotton rats [47,48] as semi-permissive hosts of human adenovi-
ruses concludes that if adenoviruses can gain access they can
propagate in any host species or cell type. It is significant because it
indicates a possible use of adenovirus-mediated gene delivery for
hematological malignancy research. Also, in light of the speed and
efficiency of adenovirus transduction, T cells can be used as cell
carriers to deliver adenovirus for gene therapy.
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Figure S1 Replication efficiency of Ad-WT and Ad-RGD
in permissive human lung carcinoma A549 cells. (A)
Adenoviral E1A gene copy number in Ad-RGD treated cells (black
bar) in comparison to Ad-WT treated cells (white bar) at different
time-points after virus transduction calculated by qPCR. (B) Bar
diagram of flow-cytometric analysis showing percentage of A549
cells expressing viral hexon antigen at different time-points after
virus transduction. Ad-RGD transduced A549 cells are represent-
ed by black bars and Ad-WT treated cells by white bars. Error bars
represent mean + SD.
(TIF)
Author Contributions
Conceived and designed the experiments: SS IVU MSL. Performed the
experiments: SS IVU BT AUA. Analyzed the data: SS. Contributed
reagents/materials/analysis tools: SS IVU AUA. Wrote the paper: SS
MSL.
References
1. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, et al. (1998) The
murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses.
J Virol 72: 415–419.
2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al.
(1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses
2 and 5. Science 275: 1320–1323.
3. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v
beta 3 and alpha v beta 5 promote adenovirus internalization but not virus
attachment. Cell 73: 309–319.
4. Huang S, Endo RI, Nemerow GR (1995) Upregulation of integrins alpha v beta
3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates
adenovirus-mediated gene delivery. J Virol 69: 2257–2263.
5. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and
mouse cellular receptors for subgroup C adenoviruses and group B
coxsackieviruses. Proc Natl Acad Sci U S A 94: 3352–3356.
6. Schmidt MR, Piekos B, Cabatingan MS, Woodland RT (2000) Expression of a
human coxsackie/adenovirus receptor transgene permits adenovirus infection of
primary lymphocytes. J Immunol 165: 4112–4119.
7. Abe J, Wakimoto H, Tsunoda R, Okabe S, Yoshida Y, et al. (1996) In vivo
antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-
gamma by adenovirus-mediated genetic transduction. Biochem Biophys Res
Commun 218: 164–170.
8. Chen Z, Ahonen M, Hamalainen H, Bergelson JM, Kahari VM, et al. (2002)
High-efficiency gene transfer to primary T lymphocytes by recombinant
adenovirus vectors. J Immunol Methods 260: 79–89.
9. Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, et al. (1994) Adoptive
immunotherapy with murine tumor-specific T lymphocytes engineered to
secrete interleukin 2. Cancer Res 54: 5757–5760.
10. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, et al. (1998) An
adenovirus vector with genetically modified fibers demonstrates expanded
Figure 7. Efficient in vivo transduction of mouse T cells by Ad-
RGD. Three groups of B6 mice were injected via tail-vein with Ad-WT
(open squares),A d - R G D(open triangles) and PBS (open circles)
respectively. Animals were sacrificed at 0, 3, 6, 9, 16, 24, 72 and 96 h
after virus injection and spleens were harvested. Splenocytes were
surface stained for CD4 and CD8 and then fixed and permeablized and
stained with anti-hexon antibody for flow-cytometric analysis of
adenovirus infected splenic T cells. Percentage of CD4
+ T cells
expressing adenoviral hexon antigen is represented in upper panel
and CD8
+ T cells are in lower panel. Error bars indicate standard
deviation from three animals per group of study. (*p,0.01;**p.0.05;
N=3)
doi:10.1371/journal.pone.0018091.g007
Ad-Mediated T Cell Transduction
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e18091tropism via utilization of a coxsackievirus and adenovirus receptor-independent
cell entry mechanism. J Virol 72: 9706–9713.
11. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A (2004) Conditionally replication-
competent adenoviral vectors with enhanced infectivity for use in gene therapy
of melanoma. Hum Gene Ther 15: 637–647.
12. Okada N, Iiyama S, Okada Y, Mizuguchi H, Hayakawa T, et al. (2005)
Immunological properties and vaccine efficacy of murine dendritic cells
simultaneously expressing melanoma-associated antigen and interleukin-12.
Cancer Gene Ther 12: 72–83.
13. Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency:
implications for the development of new therapeutic strategies. Retrovirology 6:
111.
14. Vera JF, Brenner MK, Dotti G (2009) Immunotherapy of human cancers using
gene modified T lymphocytes. Curr Gene Ther 9: 396–408.
15. Kennedy-Nasser AA, Brenner MK (2007) T-cell therapy after hematopoietic
stem cell transplantation. Curr Opin Hematol 14: 616–624.
16. Sengupta S, Jayaraman P, Chilton PM, Casella CR, Mitchell TC (2007)
Unrestrained glycogen synthase kinase-3 beta activity leads to activated T cell
death and can be inhibited by natural adjuvant. J Immunol 178: 6083–6091.
17. Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, et al. (2009)
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-
cell receptor gene transfer with lentiviral vectors. Cancer Res 69: 9385–9394.
18. Evans JD, Hearing P (2002) Adenovirus Replication. In: Curiel DT, Douglas JT,
eds. Adenoviral Vectors. San Diego, CA: Academic Press. pp 39–70.
19. Nevins JR, DeGregori J, Jakoi L, Leone G (1997) Functional analysis of E2F
transcription factor. Methods Enzymol 283: 205–219.
20. Wattel E, Vanrumbeke M, Abina MA, Cambier N, Preudhomme C, et al.
(1996) Differential efficacy of adenoviral mediated gene transfer into cells from
hematological cell lines and fresh hematological malignancies. Leukemia 10:
171–174.
21. Hurez V, Dzialo-Hatton R, Oliver J, Matthews RJ, Weaver CT (2002) Efficient
adenovirus-mediated gene transfer into primary T cells and thymocytes in a new
coxsackie/adenovirus receptor transgenic model. BMC Immunol 3: 4.
22. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, et al. (1997) Targeted
adenovirus-mediated gene delivery to T cells via CD3. J Virol 71: 7663–7669.
23. Schroers R, Hildebrandt Y, Hasenkamp J, Glass B, Lieber A, et al. (2004) Gene
transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric
adenoviral vectors. Exp Hematol 32: 536–546.
24. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M (2004)
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 104:
2272–2280.
25. Di Nicola M, Milanesi M, Magni M, Bregni M, Carlo-Stella C, et al. (1999)
Recombinant adenoviral vector-lipofectAMINE complex for gene transduction
into human T lymphocytes. Hum Gene Ther 10: 1875–1884.
26. Yang Y, Wilson JM (1995) Clearance of adenovirus-infected hepatocytes by
MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155: 2564–2570.
27. Harui A, Roth MD, Vira D, Sanghvi M, Mizuguchi H, et al. (2006) Adenoviral-
encoded antigens are presented efficiently by a subset of dendritic cells
expressing high levels of alpha(v)beta3 integrins. J Leukoc Biol 79: 1271–1278.
28. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP (2002) Adenovirus
infection enhances dendritic cell immunostimulatory properties and induces
natural killer and T-cell-mediated tumor protection. Cancer Res 62: 5260–5266.
29. Okada N, Masunaga Y, Okada Y, Iiyama S, Mori N, et al. (2003) Gene
transduction efficiency and maturation status in mouse bone marrow-derived
dendritic cells infected with conventional or RGD fiber-mutant adenovirus
vectors. Cancer Gene Ther 10: 421–431.
30. Ye Z, Shi M, Chan T, Sas S, Xu S, et al. (2007) Engineered CD8+ cytotoxic T
cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection
counteract immunosuppressive interleukin-10-secreting lung metastasis and solid
tumors. Cancer Gene Ther 14: 661–675.
31. Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, et al. (2006)
Enhanced transduction of malignant glioma with a double targeted Ad5/3-
RGD fiber-modified adenovirus. Mol Cancer Ther 5: 2408–2416.
32. Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, et al. (2007) Fiber-knob
modifications enhance adenoviral tropism and gene transfer in malignant
glioma. J Gene Med 9: 151–160.
33. Tekant Y, Davydova J, Ramirez PJ, Curiel DT, Vickers SM, et al. (2005)
Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 137: 527–535.
34. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, et al. (2004) Gene transfer
to cervical cancer with fiber-modified adenoviruses. Int J Cancer 111: 698–704.
35. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, et al. (2002) Double
modification of adenovirus fiber with RGD and polylysine motifs improves
coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum
Gene Ther 13: 1647–1653.
36. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, et al. (2008)
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to
intracranial glioma. Stem Cells 26: 831–841.
37. Harui A, Roth MD, Sanghvi M, Vira D, Mizuguchi H, et al. (2006)
Centrifugation enhances integrin-mediated transduction of dendritic cells by
conventional and RGD-modified adenoviral vectors. J Immunol Methods 312:
94–104.
38. Nandi S, Ulasov IV, Rolle CE, Han Y, Lesniak MS (2009) A chimeric
adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
J Gene Med 11: 1005–1011.
39. Lecoeur H, Ledru E, Prevost MC, Gougeon ML (1997) Strategies for
phenotyping apoptotic peripheral human lymphocytes comparing ISNT,
annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods
209: 111–123.
40. Sengupta S, Chilton PM, Mitchell TC (2005) Adjuvant-induced survival
signaling in clonally expanded T cells is associated with transient increases in
pAkt levels and sustained uptake of glucose. Immunobiology 210: 647–659.
41. Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, et al. (2007) Survivin-driven
and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in
established intracranial glioma. Hum Gene Ther 18: 589–602.
42. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, et al. (2000)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma
effect in vivo. Oncogene 19: 2–12.
43. Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, et al. (2009) In vivo
retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced
hepatotoxicity and improved tumor uptake following systemic delivery. J Virol
83: 6416–6428.
44. Garnett CT, Erdman D, Xu W, Gooding LR (2002) Prevalence and
quantitation of species C adenovirus DNA in human mucosal lymphocytes.
J Virol 76: 10608–10616.
45. McNees AL, Mahr JA, Ornelles D, Gooding LR (2004) Postinternalization
inhibition of adenovirus gene expression and infectious virus production in
human T-cell lines. J Virol 78: 6955–6966.
46. Zhang Y, Huang W, Ornelles DA, Gooding LR (2010) Modeling adenovirus
latency in human lymphocyte cell lines. J Virol 84: 8799–8810.
47. Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, et al. (2009)
Biodistribution of an oncolytic adenovirus after intracranial injection in
permissive animals: a comparative study of Syrian hamsters and cotton rats.
Cancer Gene Ther 16: 362–372.
48. Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, et al. (2010) Bone
Marrow Mesenchymal Stem Cells Loaded With an Oncolytic Adenovirus
Suppress the Anti-adenoviral Immune Response in the Cotton Rat Model. Mol
Ther 18: 1846–1856.
Ad-Mediated T Cell Transduction
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e18091